ARCT
USDArcturus Therapeutics Holdings Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$9.170
Haut
$9.400
Bas
$8.840
Volume
1.18M
Fondamentaux de l'Entreprise
Capitalisation Boursière
242.5M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
1.22M
Bourse
NGM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $60 to $12.
Citigroup Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12
Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics from Buy to Neutral and lowers the price target from $49 to $12.
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $23
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics with a Buy and lowers the price target from $48 to $23.
Guggenheim Downgrades Arcturus Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics from Buy to Neutral.
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.